Given the different molecular and RNA expression features existing among various subtypes of gliomas, the predictive value of MGMT promoter methylation in other types of glioma remains controversial, possibly because the cutoff value used in IDH-wildtype GBM has also been used to assess the role of MGMT promoter methylation in other types of glioma25,26,30,38,49. Here, IDH2 is linked to central nervous system cancer.